Influence of sodium desoxyribonucleate on anti-infectious protection and hematopoiesis in patients with polytrauma (randomized prospective, double-blind, placebo-controlled study)

The  aim of the study was to evaluate  the effect of sodium  deoxyribonucleate on anti-infectious resistance and hematopoiesis in patients with polytraumas. A single-center study of sodium  deoxyribonucleate effectiveness approved by the local Ethics Committee (protocol No. 4 05/18/2016), was conducted in 54 patients with polytrauma. The  main  group  included 27 people, at the mean  age of 39 (29-51)  years old; ISS severity score,  26 (22-34). The  comparison group  comprised 27 people, mean  age,  40 years old (26-53), mean  ISS severity score was 25 points (20 to 29). The patients with randomly attributed even numbers were injected with 5 ml preparation from vials of even-numbered series, the patients with odd numbers were treated with preparation from the odd-numbered series. They were injected intramuscularly daily from day 1 to day 10 after the injury. Before treatment, as well as on days 8, 15 after injury, peripheral blood was examined for leukocyte, erythrocyte counts, hemoglobin, total  protein, blood  IL-6, CRP; proportion of CD117⁺  and  CD34⁺  mononuclear cells, CD14⁺ monocytes, CD14⁺ granulocytes, HLA-DR⁺  mononuclear cells, defensin + granulocytes.

On  the  day  +8,   patients from  the  main  group,  against  the  comparison group  showed  an  increase   in lymphocytes, monocytes, CD117⁺ and CD34⁺ cell counts. Serum IL-6 and CRP were decreased in both groups of the patients to a similar  degree. Terms  of hospitalization in the main  group were 32.8 days, against  39.6 in comparison group. The number of complications per 1 case was, respectively, 21 versus 39, thus being 1.8 times less than  in comparison group.  When developing complications, anemia (Hb  < 90 g/l),  or hypoproteinaemia (< 60 g/l) in the main group was, respectively, 2.5and 3.5-fold  less than  in the comparison group.

Treatment with sodium  deoxyribonucleate in polytrauma may promote migration of blood precursors to the bloodstream, increase anti-infectious properties of leukocytes, reduce duration of anemia and hypoproteinemia, number of complications and decrease the terms of hospitalization.

1. Bagnenko S.F., Pivovarova L.P., Osipova I.V., Malyshev M.E., Ariskina O.B. The state of granulocytopoiesis in patients with severe sepsis that developed after combined mechanical trauma. Infektsii v khirurgii = Infections in Surgery, 2013, no. 1, pp. 44-48. (In Russ.)

2. Bagnenko S.F., Pivovarova L.P., Osipova I.V., Malyshev M.E., Ariskina O.B. Post-traumatic anemia in patients with severe mechanical injury. Skoraya meditsinskaya pomoshch = Emergency Medical Care, 2013, Vol. 14, no. 4, pp. 41-46. (In Russ.)

3. Besednova N.N., Zaporozhets T.S. The effect of prokaryotes deoxyribonucleic acid on humoral and cellular factors of innate and adaptive vertebrate immunity. Tikhookeanskiy meditsinskiy zhurnal = Pacific Medical Journal, 2009, no. 3, pp. 8-12. (In Russ.)

4. Budikhina A.S., Pinegin B.V. α-Defensins – antimicrobial peptides of neutrophils: properties and functions. Immunologiya = Immunology, 2008, no. 5, pp. 317-320. (In Russ.)

5. Gromov M.I., Pivovarova L.P. The use of the immunomodulator derinat in the treatment of surgical patients with severe sepsis. Fundamentalnyye issledovaniya = Fundamental Research, 2012, no. 7, pp. 289-295. (In Russ.)

6. Zemskov A.M., Zemskov V.M., Petrov A.V., Nikitin A.V. To the mechanism of stimulation of immunogenesis by sodium nucleinate. Immunologiya = Immunology, 1981, no. 1, pp. 52-55. (In Russ.)

7. Ivchenko D.R., Pivovarova L.P., Tulupov A.N. Immunoprophylaxis of post-traumatic pleural empyema. Skoraya meditsinskaya pomoshch = Emergency Medical Care, 2004, Vol. 5, no. 1, pp. 159-160. (In Russ.)

8. Kaplina E.N., Weinberg Yu.P. Derinat is a natural immunomodulator for children and adults. Ed. 3rd, fix and add.]. Moscow: Scientific Book, 2007. 240 p.

9. Kokryakov V.N., Kovalchuk L.V., Aleshina G.M., Shamova O.V. Cationic antimicrobial peptides as molecular factors of immunity:multifunctionality. Zhurnal mikrobiologii epidemiologii i immunologii = Journal of Microbiology Epidemiology and Immunology, 2006, no. 2, pp. 98-105. (In Russ.)

10. Lebedev V.F., Gavrilin S.V., Kirov M.Yu., Neymark M.I. , Levit A.L., Malkova O.G., Ostanin A.A., Chernykh E.R., Streltsova E.I., Kon E.M., Nikolenko A.V., Lebedev M.F., Chernyshkova M.V., Vashchenkov V.V., Rud A.A. The results of a multicenter prospective controlled study of the effectiveness of the drug recombinant human interleukin-2 (roncoleukin) in the complex intensive care of severe sepsis. Intensivnaya terapiya = Intensive Care, 2007, no. 3, pp. 20-31. (In Russ.)

11. Malyshev M.E., Sadulayev D.Sh., Ariskina O.B., Popenko L.N. Bacterial translocation into the systemic circulation in patients with combined trauma. Vestnik Avitsenny = Bulletin of Avicenna, 2012. Vol. 53, no. 4, pp. 53-56. (In Russ.)

12. Polovinkina V.S., Markov E.Yu. The structure and immunoadjuvant properties of CpG-DNA. Meditsinskaya immunologiya = Medical Immunology (Russia), 2010, Vol. 12, no. 6, pp. 469-476. (In Russ.) doi: 10.15789/1563-0625-2010-6-469-476.

13. Rusinova T.V. The mechanism of influence of nucleic acid preparations on the production of pro-inflammatory cytokines in vitro in the norm and in the infectious process. Sovremennyye problemy nauki i obrazovaniya = Modern Problems of Science and Education, 2016, no. 3, pp. 11-14. (In Russ.)

14. Seleznev S.A., Bagnenko S.F., Shapot Yu.B., Kurygin A.A. Traumatic disease and its complications]. St. Petersburg: Polytechnic, 2004. 414 p.

15. Filatov O.Yu., Kashaeva O.V., Bugrimov D.Yu., Klimovich A.A. Morphophysiological principles of the immunological action of eukaryotic DNA. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2013, Vol. 7 (16), no. 4, pp. 385-390. (In Russ.)

16. Tsibin Yu.N. A multivariate assessment of the severity of traumatic shock in a clinic. Vestnik khirurgii im. I.I. Grekova = Grekov’s Bulletin of Surgery, 1980, Vol. 125, no. 9, pp. 62-67. (In Russ.)

17. Baker S.P., O’Neill B. The injury severity score: update. J. Trauma, 1976, Vol. 16, no. 11, pp. 882-885.

18. Ballas Z.K. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunologic Research, 2007, Vol. 39, no. 1-3, pp. 15-21.

19. Edling C.E., Hallberg B. c-Kit – a hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol., 2007, Vol. 39, no. 11, pp. 1995-1998.

20. Goerdt S., Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity, 1999, no. 10, pp. 137-142.

21. Goldfarb Y., Levi B., Sorski L., Frenkel D., Ben-Eliyahu S. СpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: Potential implications for clinical use. Brain Behav. Immun., 2011. Vol. 25, no. 1, pp. 67-76.

22. Lee M.L. Strand V. Intravenous immunoglobulins in clinical practice. Marcel Dekker. New York, Basel, Hong Kong, 1997. 509 p.

23. Liu J., Rybakina E.G., Korneva E.A. Noda M. Effects of Derinat on ischemia-reperfusion-induced pressure ulcer mouse model. J. Pharmacol. Sci., 2018, Vol. 138, no. 2, pp. 123-130.

24. Schetter C., Vollmer J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for Toll-like receptor 9. Curr. Opin. Drug Discov. Dev., 2004, Vol. 7, no. 2, pp. 204-210.

25. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev., 2009, Vol. 61, no. 3, pp. 195-204.

26. Vollmer J., Weeratna R.D., Jurk M., Samulowitz U., Mccluskie M.J., Payette P., Davis H.L., Schetter C., Krieg A.M. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology, 2004, Vol. 113, no. 2, pp. 212-223.